Compositions and methods for treating eye infections and disease
AssigneeUniversity of Virginia Patent Foundation
InventorGordon W. Laurie
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.
Claims30
A sterile, aqueous pharmaceutical composition for topical administration to an ocular surface, the composition comprising:
- a peptide, or a pharmaceutically acceptable salt thereof,
- wherein the peptide, or a pharmaceutically acceptable salt thereof, has an amino acid sequence consisting of SEQ ID NO:
- 5,
- wherein the C-terminus of the peptide is amidated,
- wherein the N-terminus of the peptide is acetylated, and a pharmaceutically acceptable aqueous carrier,
- wherein the sterile, aqueous pharmaceutical composition is suitable for topical administration to an ocular surface of a subject, and
- wherein the sterile, aqueous pharmaceutical composition is free of any type of enzymatic, chemical or biochemical molecule capable of breakdown of the peptide at its termini that is sequential degradation of the peptide at a terminal end thereof in the absence of the C-terminus amidation and the N-terminus acetylation.
A method of treating dry eye, the method comprising:
- topically administering a therapeutically effective amount of a sterile, aqueous, topical pharmaceutical composition to an ocular surface,
- wherein the sterile aqueous topical pharmaceutical composition comprises:
- a peptide, or a pharmaceutically acceptable salt thereof,
- wherein the peptide, or pharmaceutically acceptable salt thereof, has an amino acid sequence consisting of SEQ ID NO:
- 5,
- wherein the C-terminus of the peptide is amidated,
- wherein the N-terminus of the peptide is acetylated, and
- a pharmaceutically acceptable aqueous carrier,
- wherein the sterile, aqueous pharmaceutical composition is suitable for topical administration to an ocular surface of a subject, and
- wherein the sterile, aqueous pharmaceutical composition is free of any type of enzymatic, chemical or biochemical molecule capable of breakdown of the peptide at its termini that is sequential degradation of the peptide at a terminal end thereof in the absence of the C-terminus amidation and the N-terminus acetylation.
Dependencies are inferred from the claim text.